Press release
Schizophrenia Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Reviva Pharmaceuticals, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharmaceuticals, Boehringer Ingelheim, Sunovion Pharmaceu
To Know in detail about the Schizophrenia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Schizophrenia Market Forecast
https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Schizophrenia Market Report:
• The Schizophrenia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In February 2022, Vanderbilt University partnered with Neumora Therapeutics in a global licensing and research collaboration to create precise medications for brain illnesses by combining data science and neuroscience. The agreement involves two novel compound series designed to address conditions such as schizophrenia and other neuropsychiatric disorders.
• In March 2022, AbbVie initiated a fresh co-development and licensing deal with Gedeon Richter, focusing on the exploration, development, and marketing of innovative dopamine receptor modulators intended for addressing potential treatments for neuropsychiatric ailments.
• In 2021, approximately 6.2 million prevalent cases of Schizophrenia were recorded across the 7MM. The United States exhibited the highest prevalence of Schizophrenia among the countries included in the 7MM.
• In 2021, approximately 745,000 cases of schizophrenia were reported among males, while around 716,000 cases were observed among females in the United States.
• In the EU5 region in 2021, there were around 257,000 cases of mild schizophrenia, about 418,000 cases of moderate schizophrenia, and roughly 467,000 cases of severe schizophrenia.
• Key Schizophrenia Companies: Reviva Pharmaceuticals, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharmaceuticals, Boehringer Ingelheim, Sunovion Pharmaceuticals (Sumitomo Pharma)/Otsuka Pharmaceutical, Lyndra Therapeutics, Laboratorios Farmacéuticos Rovi, Newron Pharmaceuticals, Cerevel Therapeutics, AstraZeneca, Eli Lilly and Company, Karuna Therapeutics, Neurocrine Biosciences, and others
• Key Schizophrenia Therapies: RP5063 (brilaroxazine), MIN-101 (roluperidone), KarXT (xanomeline-trospium), NUPLAZID (pimavanserin), ICELPERTIN (BI-425809), SEP-363856 (ulotaront), OKEDI (risperidone ISM), LYN-005, NW-3509/NW-3509A (evenamide), CVL-231 (emraclidine), Seroquel Sustained Release, Intramuscular Olanzapine Depot, Xanomeline and Trospium Chloride Capsules, NBI-1117568, and others
• The Schizophrenia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Schizophrenia pipeline products will significantly revolutionize the Schizophrenia market dynamics.
Schizophrenia Overview
Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, feels, and behaves. Individuals with schizophrenia may have difficulty distinguishing between what is real and what is imaginary, often experiencing delusions, hallucinations, disorganized thinking, and agitated body movements.
Get a Free sample for the Schizophrenia Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Schizophrenia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Schizophrenia Epidemiology Segmentation:
The Schizophrenia market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Schizophrenia
• Prevalent Cases of Schizophrenia by severity
• Gender-specific Prevalence of Schizophrenia
• Diagnosed Cases of Episodic and Chronic Schizophrenia
Download the report to understand which factors are driving Schizophrenia epidemiology trends @ Schizophrenia Epidemiology Forecast
https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Schizophrenia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Schizophrenia market or expected to get launched during the study period. The analysis covers Schizophrenia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Schizophrenia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Schizophrenia Therapies and Key Companies
• RP5063 (brilaroxazine): Reviva Pharmaceuticals
• MIN-101 (roluperidone): Minerva Neurosciences
• KarXT (xanomeline-trospium): Karuna Therapeutics
• NUPLAZID (pimavanserin): Acadia Pharmaceuticals
• ICELPERTIN (BI-425809): Boehringer Ingelheim
• SEP-363856 (ulotaront): Sunovion Pharmaceuticals (Sumitomo Pharma)/Otsuka Pharmaceutical
• OKEDI (risperidone ISM): Laboratorios Farmacéuticos Rovi
• LYN-005: Lyndra Therapeutics
• NW-3509/NW-3509A (evenamide): Newron Pharmaceuticals
• CVL-231 (emraclidine): Cerevel Therapeutics
• Seroquel Sustained Release: AstraZeneca
• Intramuscular Olanzapine Depot: Eli Lilly and Company
• Xanomeline and Trospium Chloride Capsules: Karuna Therapeutics
• NBI-1117568: Neurocrine Biosciences
Discover more about therapies set to grab major Schizophrenia market share @ Schizophrenia Treatment Landscape
https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Schizophrenia Market Drivers
• Increasing popularity among individuals for long-acting injectable (LAI) antipsychotics are key factors driving growth of the global schizophrenia drugs market.
Schizophrenia Market Barriers
• WHO's Comprehensive Mental Health Action Plan 2013- 2030 will further enhance the awareness about mental health by ensuring 100 million more people have access to quality and affordable care for mental health conditions.
Scope of the Schizophrenia Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Schizophrenia Companies: Reviva Pharmaceuticals, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharmaceuticals, Boehringer Ingelheim, Sunovion Pharmaceuticals (Sumitomo Pharma)/Otsuka Pharmaceutical, Lyndra Therapeutics, Laboratorios Farmacéuticos Rovi, Newron Pharmaceuticals, Cerevel Therapeutics, AstraZeneca, Eli Lilly and Company, Karuna Therapeutics, Neurocrine Biosciences, and others
• Key Schizophrenia Therapies: RP5063 (brilaroxazine), MIN-101 (roluperidone), KarXT (xanomeline-trospium), NUPLAZID (pimavanserin), ICELPERTIN (BI-425809), SEP-363856 (ulotaront), OKEDI (risperidone ISM), LYN-005, NW-3509/NW-3509A (evenamide), CVL-231 (emraclidine), Seroquel Sustained Release, Intramuscular Olanzapine Depot, Xanomeline and Trospium Chloride Capsules, NBI-1117568, and others
• Schizophrenia Therapeutic Assessment: Schizophrenia current marketed and Schizophrenia emerging therapies
• Schizophrenia Market Dynamics: Schizophrenia market drivers and Schizophrenia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Schizophrenia Unmet Needs, KOL's views, Analyst's views, Schizophrenia Market Access and Reimbursement
To know more about Schizophrenia companies working in the treatment market, visit @ Schizophrenia Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Schizophrenia Market Report Introduction
2. Executive Summary for Schizophrenia
3. SWOT analysis of Schizophrenia
4. Schizophrenia Patient Share (%) Overview at a Glance
5. Schizophrenia Market Overview at a Glance
6. Schizophrenia Disease Background and Overview
7. Schizophrenia Epidemiology and Patient Population
8. Country-Specific Patient Population of Schizophrenia
9. Schizophrenia Current Treatment and Medical Practices
10. Schizophrenia Unmet Needs
11. Schizophrenia Emerging Therapies
12. Schizophrenia Market Outlook
13. Country-Wise Schizophrenia Market Analysis (2019-2032)
14. Schizophrenia Market Access and Reimbursement of Therapies
15. Schizophrenia Market Drivers
16. Schizophrenia Market Barriers
17. Schizophrenia Appendix
18. Schizophrenia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Schizophrenia Pipeline https://www.delveinsight.com/report-store/schizophrenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Schizophrenia Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Schizophrenia market. A detailed picture of the Schizophrenia pipeline landscape is provided, which includes the disease overview and Schizophrenia treatment guidelines.
Schizophrenia Epidemiology https://www.delveinsight.com/report-store/schizophrenia-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Schizophrenia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Schizophrenia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Ischemia-reperfusion Injury Market https://www.delveinsight.com/report-store/ischemia-reperfusion-injury-market
DelveInsight's report titled "Ischemia-reperfusion injury Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes historical and projected epidemiological data concerning Ischemia-reperfusion injury. This analysis includes a breakdown of the Incident Cases of Ischemia-reperfusion injury, Organ-specific Incident Cases of Ischemia-reperfusion injury, Gender-specific Incident Cases of Ischemia-reperfusion Injury, and Age-specific Incident Cases of Ischemia-reperfusion Injury.
Meniscus Tear Market
https://www.delveinsight.com/report-store/meniscus-tear-market
DelveInsight's report titled "Meniscus Tear Market Insights, Epidemiology, and Market Forecast -2032" provides a comprehensive analysis of Meniscus Tear. The report includes a detailed examination of the historical and projected epidemiology data that includes Total Incident Cases of Meniscus Tear, Gender-specific Incident Cases of Meniscus Tear, Age-specific Incident Cases of Meniscus Tear, Treatable Cases of Meniscus Tear.
Functional Dyspepsia Market https://www.delveinsight.com/report-store/functional-dyspepsia-market-insights
DelveInsight's "Functional Dyspepsia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Functional Dyspepsia, historical and forecasted epidemiology as well as the Functional Dyspepsia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Diphtheria Market
https://www.delveinsight.com/report-store/diphtheria-market
DelveInsight's report titled "Diphtheria Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes diphtheria. The report includes a detailed examination of the historical and projected epidemiology data that includes incident cases of diphtheria segmented by age and type.
Chronic Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market
DelveInsight's report titled "Chronic Constipation Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes Chronic constipation. The report includes a detailed examination of the historical and projected epidemiology data, including Total Prevalent Cases, Diagnosed Prevalent Cases, Gender-specific Diagnosed Prevalent Cases, and Age-specific Diagnosed Prevalent cases of Chronic Constipation.
Pulmonary Fibrosis Market
https://www.delveinsight.com/report-store/pulmonary-fibrosis-market
DelveInsight's "Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Pulmonary Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Schizophrenia Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Reviva Pharmaceuticals, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharmaceuticals, Boehringer Ingelheim, Sunovion Pharmaceu here
News-ID: 3343784 • Views: …
More Releases from DelveInsight Business Research
Global Advanced Melanoma Pipeline Accelerates With 60+ Emerging Therapies, Revea …
DelveInsight's "Advanced Melanoma Pipeline Insight 2025" report delivers an in-depth analysis of more than 55 companies and over 60 investigational therapies currently advancing through the Advanced Melanoma research landscape. It offers detailed profiles of both clinical- and preclinical-stage candidates and provides a thorough evaluation of therapies based on product type, development stage, route of administration, and molecule class. The report also outlines inactive or discontinued programs within this domain.
Explore the…
Global Spasticity Treatment Landscape Set for Transformation: DelveInsight Unvei …
DelveInsight's "Spasticity Pipeline Insight, 2025" report offers an in-depth evaluation of 10+ companies and more than 12 investigational therapies currently advancing through the Spasticity treatment pipeline. The report includes detailed profiles of clinical- and preclinical-stage candidates, along with a thorough assessment of therapies by product type, development phase, route of administration, and molecular class. It also highlights discontinued and inactive programs in the field.
Stay informed with the latest developments! Access…
Lewy Body Dementia Treatment Market 2034 - Market Size, Competitive Landscape, C …
The Lewy Body Dementia (LBD) market across the seven major markets (7MM) was valued at approximately USD 670 million in 2022, with strong growth anticipated through 2034. In 2022, an estimated 11 million dementia cases were recorded across the 7MM, of which ~0.6 million were attributed to Lewy Body Dementia. Rising disease prevalence-driven by aging demographics, enhanced diagnostic capabilities, and increasing awareness-is expected to stimulate market expansion. Companies including EIP…
Bronchitis Treatment Market 2034: Market Size, Competitive Landscape, Companies, …
The bronchitis therapeutics market is projected to grow steadily from 2025-2034, driven by rising disease prevalence, technological progress, and the emergence of new treatment options. Current management focuses on symptom relief through bronchodilators, corticosteroids, and antibiotics for acute cases, while chronic bronchitis requires long-term inhaled therapies, pulmonary rehabilitation, and lifestyle changes. A key advancement is the FDA-approved OHTUVAYRE (ensifentrine), which offers dual bronchodilator and anti-inflammatory benefits. Despite progress, there is…
More Releases for Schizophrenia
Rising Mental Illness Burden Fuels Growth In The Schizophrenia Market: Critical …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Schizophrenia Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The financial scope of the schizophrenia market has shown consistent expansion lately, projected to see an increase from a valuation of $5.82 billion in 2024 to $6.06 billion by 2025, reflecting a compound annual growth rate…
Rising Mental Illness Burden Fuels Growth In The Schizophrenia Market: Pivotal F …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
Schizophrenia Market Size Growth Forecast: What to Expect by 2025?
In the past few years, the schizophrenia market size has seen robust growth. The projected growth from $5.82 billion in 2024 to $6.11 billion in 2025, signifies a compound annual growth rate (CAGR) of 5.0%. Factors such as increased…
Schizophrenia Drugs Market Opportunity | Size | Research Report
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲: Schizophrenia Drugs Market was valued at USD 5.3 Billion in 2018 and is projected to reach USD 8.42 Billion by 2026, growing at a CAGR of 3.66% from 2019 to 2026.
Market Overview for Schizophrenia Drugs Market
Schizophrenia Drugs Market OverviewThe schizophrenia drugs market is experiencing significant growth driven by advancements in pharmacotherapy and increasing awareness about mental health disorders. Schizophrenia, a chronic and severe mental disorder affecting millions…
Schizophrenia Drugs Market - Restoring Balance, Inspiring Hope: Schizophrenia Dr …
Newark, New Castle, USA: The "Schizophrenia Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Schizophrenia Drugs Market: https://www.growthplusreports.com/report/schizophrenia-drugs-market/7871
This latest report researches the industry structure, sales, revenue,…
Schizophrenia Drugs Market - Leading the Way in Schizophrenia Treatment: Nurturi …
Newark, New Castle, USA - new report, titled Schizophrenia Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Schizophrenia Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Schizophrenia Drugs market. The report offers an overview of the market, which…
Schizophrenia Drug Market & Pipeline Insight
Schizophrenia is defined as a disorder of the brain which impacts the way in which a person acts, thinks, and sees the world. It has been observed that the patients suffering from schizophrenia generally tend to have an altered perception of reality, which reveals a significant diversion from the reality. In most cases, schizophrenia is diagnosed among people in the late teens or early adulthood. However, middle-aged people also could…
